With FDA Nod, Nonprofit Biotech Launches New IUD—And New edition
An peculiar ladies’s health biopharma with an awfully atypical strategy has handed its first giant test.
The FDA mentioned these days that Medicines360 can deliver a contraceptive to market. That’s not the ordinary part, and neither is the product. It’s an intrauterine tool, and IUDs were round for a century in one form or some other.
What’s odd is that San Francisco-primarily based Medicines360 is a nonprofit.
There were different nonprofit biotech companies. but Medicines360 wants to maintain itself thru product gross sales, now not donations, and the FDA determination opens the door to that effort.
Now comes the 2d part of the check. Medicines360 will lean on its marketing associate, the pharma giant Actavis (NYSE: ACT), of Dublin, ireland, to make the sales.
Actavis will promote the IUD in the U.S. at market costs underneath the identify Liletta. Medicines360 will use its lower of these sales to subsidize get admission to to the product at clinics that serve decrease-earnings women.
If Actavis doesn’t deliver the products, Medicines360′s technique will likely be for naught. Chief running officer Pamela Weir (pictured) says she isn’t concerned. “Actavis has an incredible ladies’s well being gross sales power within the non-public sector,” she says.
Actavis spokesman David Belian wouldn’t provide a headcount of salespeople, however he stated the corporate already has seven women’s well being products that it sells to 25,000 healthcare mavens within the U.S. Belian additionally declined to present sales projections. The U.S. contraceptive market is $ 1 billion and growing, he said.
I asked Weir about potential tumult, due to Actavis’s reputedly steady involvement in mergers and acquisitions. large pharma reorganizations can also be deadly to smaller partners, who see their inner allies shuffled to new positions or brushed aside altogether. Weir isn’t worried about that, both: In mergers, she says, “model teams” are normally left to “do their factor.” (One shakeup that may’t be evaded: Actavis just merged with Allergan and will undertake the Allergan title except for in a number of make a choice markets.)
Weir speaks from experience. She’s a 25-yr pharma veteran, most not too long ago serving as vice chairman of marketing at sprawling area of expertise pharma corporations King prescription drugs and Nycomed—now a part of Pfizer (NYSE: PFE) and Takeda Pharmaceutical, respectively—that have identical companies to Actavis.
there is at least one incidence of a nonprofit biotech firm: OneWorld health, additionally in San Francisco, which was founded in 2000 and merged with Seattle’s nonprofit course in 2011. Its founder, Victoria Hale, based Medicines360, sits on the board, and led the medical construction of Liletta.
OneWorld well being relied on donations to do construction work on infectious disease treatments. Medicines360 has additionally required donations—it was once launched with a 5-12 months funding commitment from an anonymous donor to hold it via a 1,750-individual phase 3 clinical trial—however it now needs to prove it can be self-sustaining with its two-tier model.
Why begin with IUDs? Weir says the anonymous donor wished to fund an effort to lower unwanted pregnancies, and beginning keep watch over tablets aren’t nearly as efficient for a number of causes. girls put out of your mind to take them, they usually don’t just like the side effects. as a result of capsules aren’t all the time used properly, the failure price is around 9 p.c, in step with the U.S. centers for disease regulate and Prevention. The failure rate for the kind of Medicines360′s IUD, which the FDA authorized for 3-yr use, releasing a small quantity of the contraceptive levonorgestrel every day, is zero.2 p.c.
IUDs had a bad popularity for a long time, the legacy of a controversial product referred to as … next page »
(124)
